Search in the Abstract Database

Search Abstracts 2013

* = Presenting author

P496. Hemophagocytic syndrome during inflammatory bowel disease (IBD): a serious and unfamiliar complication of immunosuppressive therapy

C. Stefanescu1, M. Allez2, G. Cadiot3, M. Fumery4, A. Amiot5, D. Laharie6, G. Savoye7, J.M. Gornet2, P. Seksik8, X. Treton1, H. Duboc9, E. Fort10, C. Bloch-Quyerat11, Y. Bouhnik1, 1Hôpital Beaujon, Clichy, France, 2Hôpital Saint Louis, Paris, France, 3CHU Reims, Reims, France, 4CHU Amiens, Amiens, France, 5Hôpital Henri Mondor, Creteil, France, 6CHU Bordeaux, Bordeaux, France, 7CHU Rouen, Rouen, France, 8Hôpital Saint Antoine, Paris, France, 9Hôpital Louis Mourier, Colombes, France, 10CHR Orleans, Orleans, France, 11Hôpital George Pompidou, Paris, France

Background

Hemophagocytic syndrome (HLH), characterized by inappropriate activation of macrophages resulting in phagocytosis of all bone marrow derived cells, mainly occurs in immunocompromised hosts. IBD patients treated with immunosuppressive drugs have an increased risk to develop HLH. The aim of our study was to describe the characteristics of patients with IBD associated with HLH and determine the prognosis.

Methods

Retrospective multicenter study conducted by the GETAID.

Results

Between 2003 and 2012, 10/43 GETAID centers identified 27 patients (8 M/19 F): 24 patients followed for CD, 2 for UC and one for indeterminate colitis. The mean age at diagnosis of HLH was 35 years (range 19–61). Twenty five patients were under thiopurines in monotherapy (n = 17), in combination with steroids (n = 3), anti-TNF (n = 4) or both (n = 1); one patient received anti-TNF in monotherapy and one patient was on steroids, tacrolimus and mycophenolate mophetil. At the time of diagnosis, immunosuppressive drugs were discontinued in all patients.

The clinical features were: fever (39–40°C) (27/27), rash (9/27), lymphadenopathy (11/27), splenomegaly (11/26), dyspnea (8/27), neurological disorders (5/27). Bicytopenia was observed in 23/27 patients. The mean fasting triglycerides was 3.4 mmol/L (range 1.3–6.3 mmol/L) and the serum ferritin 12496 mg/L (range 746–99393). Hemophagocytosis was observed on bone marrow aspiration in 19/23 (83%) patients.

A pathogen was identified as the precipitating cause of HLH in all subjects: CMV (n = 10), EBV (n = 10), HHV1 (n = 2), parvovirus B19 (n = 2), BK (n = 2), K oxytoca and E aerogenes (n = 1). Lymphoproliferative disorders [B lymphoma (n = 3) and T-cell lymphoma (n = 1)] were associated in 4 cases. A specific treatment for HLH was administered in 18 patients: immunoglobulins (n = 10), steroids (n = 11), etoposide (n = 7), cyclosporine (n = 1).

Six patients died (22%), in whom HLH was related to EBV infection (n = 4), CMV infection (n = 1) and HHV1 infection (n = 1). At the latest follow-up (average 27 months, range 0.1 to 100), 3 patients were in clinical remission without treatment, 4 patients underwent surgical resection, 3 patients received 5ASA, 1 patient steroids and 5 patients anti-TNF therapy. Thiopurine was restarted in 4 patients.

Conclusion

In all IBD patients under immunosuppressants, a febrile cytopenia should alert to the possibility of an HLH. Early diagnosis, identification of the causative agent and appropriate treatment could reduce the mortality of this life threatening conditions.